Seizures in patients with IDH-mutated lower grade gliomas

J Neurooncol. 2022 Nov;160(2):403-411. doi: 10.1007/s11060-022-04158-6. Epub 2022 Oct 18.

Abstract

Purpose: Most patients with Lower Grade Gliomas (LGG) present with epileptic seizures. Since the advent of molecular diagnostics, more homogenous sub-entities have emerged, including the isocitrate dehydrogenase-mutated (IDH-mutated) astrocytomas and 1p19q-codeleted oligodendrogliomas. We aimed to describe the occurrence of seizures in patients with molecularly defined LGG pre- and postoperatively and to analyze factors affecting seizure status postoperatively.

Methods: A population-based cohort of 130 adult patients with IDH-mutated WHO grade 2 or 3 astrocytomas and oligodendrogliomas was assessed pertaining to seizure burden before and after surgery.

Results: Fifty-four (79.4%) patients with astrocytoma and 45 (72.6%) patients with oligodendroglioma had a history of seizures before surgery. At 12 months postoperatively, 51/67 (76.1%) patients with astrocytoma and 47/62 (75.8%) patients with oligodendrogliomas were seizure free. In a multivariable logistic regression analysis, lower extent of resection (EOR) (OR 0.98; 95% CI 0.97-1.00, p = 0.01) and insular tumor location (OR 5.02; 95% CI 1.01-24.87, p = 0.048) were associated with presence of seizures within 1 year postoperatively in the entire LGG cohort. In sub-entities, EOR was in a similar manner associated with seizures postoperatively in astrocytomas (OR 0.98; 95% CI 0.96-0.99, p < 0.01) but not in oligodendrogliomas (p = 0.34).

Conclusion: Our results are well in line with data published for non-molecularly defined LGG with a large proportion of patients being seizure free at 1 year postoperative. Better seizure outcome was observed with increased EOR in astrocytomas, but this association was absent in oligodendrogliomas.

Keywords: 1p19q; EOR; Epilepsy; IDH-mutation; Lower grade glioma; Seizures.

MeSH terms

  • Adult
  • Astrocytoma* / complications
  • Astrocytoma* / genetics
  • Astrocytoma* / surgery
  • Brain Neoplasms* / complications
  • Brain Neoplasms* / genetics
  • Brain Neoplasms* / surgery
  • Glioma* / complications
  • Glioma* / genetics
  • Glioma* / surgery
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Mutation
  • Oligodendroglioma* / complications
  • Oligodendroglioma* / genetics
  • Oligodendroglioma* / surgery
  • Seizures / genetics

Substances

  • Isocitrate Dehydrogenase